1. Home
  2. NAZ vs ENTX Comparison

NAZ vs ENTX Comparison

Compare NAZ & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Arizona Quality Municipal Income Fund

NAZ

Nuveen Arizona Quality Municipal Income Fund

HOLD

Current Price

$10.98

Market Cap

162.0M

Sector

Finance

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.75

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAZ
ENTX
Founded
1992
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.0M
147.4M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
NAZ
ENTX
Price
$10.98
$2.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
25.4K
★ 365.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
★ 3.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 0.22
Revenue
N/A
★ $42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$12.73
Revenue Growth
★ N/A
N/A
52 Week Low
$10.99
$0.91
52 Week High
$13.42
$4.20

Technical Indicators

Market Signals
Indicator
NAZ
ENTX
Relative Strength Index (RSI) 12.49 42.73
Support Level N/A $2.71
Resistance Level $12.59 $2.78
Average True Range (ATR) 0.36 0.18
MACD -0.09 -0.03
Stochastic Oscillator 0.62 15.22

Price Performance

Historical Comparison
NAZ
ENTX

About NAZ Nuveen Arizona Quality Municipal Income Fund

Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: